Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

By sjmartinez • April 1, 2025

Singh S, Nguyen JD, Fudman DI, Gerich ME, Shah SA, Hudesman D, McConnell RA, Lukin DJ, Flynn AD, Hwang C, Sprung B, Gaidos JKJ, Mattar MC, Rubin DT, Hashash JG, Metwally M, Ali T, Ma C, Hoentjen F, Narula N, Bessissow T, Rosenfeld G, McCurdy JD, Ananthakrishnan AN, Cross RK, Rodriguez Gaytan JR, Gurrola ES, Patel S, Siegel CA, Melmed GY, Weaver SA, Power S, Zou G, Jairath V, Hou JK. Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial. BMJ Open Gastroenterol. 2025 Mar 31;12(1):e001615. doi: 10.1136/bmjgast-2024-001615. PMID: 40164445.

Tags: Cedars Sinai DoM, Crohn’s disease, Digestive Diseases, immunotherapy, inflammatory bowel disease, Publications

Metabolic Niches: MALDI Imaging Reveals Lipidomic Heterogeneity in the Human Heart

Osumi KM, Kransdorf EP, Manzoor D, Karlstaedt A, Neumann EK. Metabolic Niches: MALDI Imaging Reveals Lipidomic Heterogeneity in the Human Heart. J Am Soc Mass[...]

Prognostic Significance of Early Donor-derived Cell-free DNA Trajectories After Kidney Transplantation

Sureshkumar K, Klein JA, Kumar D, Costa N, Glehn-Ponsirenas R, Chuang P, Shen L, Lu J, Wojciechowski D, Jain P, Huang Y, Wiseman A, Huang[...]

Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants

Reeder HT, Donohue SE, Martin JN, Hornig M, Mosier JM, Ashktorab H, Atieh O, Blomkalns AL, Brim H, Chen Y, Cortez MM, Erdmann NB, Fang[...]